Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Oncotarget ; 6(34): 36762-73, 2015 Nov 03.
Article in English | MEDLINE | ID: mdl-26447611

ABSTRACT

CD44 expression is elevated in basal-like breast cancer (BLBC) tissue, and correlates with increased efficiency of distant metastasis in patients and experimental models. We sought to characterize mechanisms underpinning CD44-promoted adhesion of BLBC cells to vascular endothelial monolayers and extracellular matrix (ECM) substrates. Stimulation with hyaluronan (HA), the native ligand for CD44, increased expression and activation of ß1-integrin receptors, and increased α5-integrin subunit expression. Adhesion assays confirmed that CD44-signalling potentiated BLBC cell adhesion to endothelium and Fibronectin in an α5B1-integrin-dependent mechanism. Co-immunoprecipitation experiments confirmed HA-promoted association of CD44 with talin and the ß1-integrin chain in BLBC cells. Knockdown of talin inhibited CD44 complexing with ß1-integrin and repressed HA-induced, CD44-mediated activation of ß1-integrin receptors. Immunoblotting confirmed that HA induced rapid phosphorylation of cortactin and paxillin, through a CD44-dependent and ß1-integrin-dependent mechanism. Knockdown of CD44, cortactin or paxillin independently attenuated the adhesion of BL-BCa cells to endothelial monolayers and Fibronectin. Accordingly, we conclude that CD44 induced, integrin-mediated signaling not only underpins efficient adhesion of BLBC cells to BMECs to facilitate extravasation but initiates their adhesion to Fibronectin, enabling penetrant cancer cells to adhere more efficiently to underlying Fibronectin-enriched matrix present within the metastatic niche.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cortactin/metabolism , Fibronectins/metabolism , Hyaluronan Receptors/metabolism , Integrin alpha5beta1/metabolism , Paxillin/metabolism , Breast Neoplasms/genetics , Cell Adhesion/physiology , Cell Line, Tumor , Female , Humans , Integrin alpha5beta1/biosynthesis , Signal Transduction
2.
Oncotarget ; 6(13): 11465-76, 2015 May 10.
Article in English | MEDLINE | ID: mdl-25888636

ABSTRACT

Metastasis is the predominant cause of death from cancer yet we have few biomarkers to predict patients at increased risk of metastasis and are unable to effectively treat disseminated disease. Analysis of 448 primary breast tumors determined that expression of the hylauronan receptor CD44 associated with high grade (p = 0.046), ER- (p = 0.001) and PR-negative tumors (p = 0.029), and correlated with increased distant recurrence and reduced disease-free survival in patients with lymph-node positive or large tumors. To determine its functional role in distant metastasis, CD44 was knocked-down in MDA-MB-231 cells using two independent shRNA sequences. Loss of CD44 attenuated tumor cell adhesion to endothelial cells and reduced cell invasion but did not affect proliferation in vitro. To verify the importance of CD44 to post-intravasation events, tumor formation was assessed by quantitative in vivo imaging and post-mortem tissue analysis following an intra-cardiac injection of transfected cells. CD44 knock-down increased survival and decreased overall tumor burden at multiple sites, including the skeleton in vivo. We conclude that elevated CD44 expression on tumour cells within the systemic circulation increases the efficiency of post-intravasation events and distant metastasis in vivo, consistent with its association with increased distant recurrence and reduced disease-free survival in patients.


Subject(s)
Breast Neoplasms/metabolism , Cell Movement , Hyaluronan Receptors/metabolism , Animals , Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Cell Adhesion , Cell Line, Tumor , Cell Survival , Disease-Free Survival , Female , Gene Knockdown Techniques , Humans , Hyaluronan Receptors/genetics , Kaplan-Meier Estimate , Lymphatic Metastasis , Mice, Nude , Middle Aged , Neoplasm Grading , Phenotype , Proportional Hazards Models , RNA Interference , Risk Factors , Signal Transduction , Time Factors , Transfection , Tumor Burden
3.
Adv Exp Med Biol ; 773: 323-51, 2014.
Article in English | MEDLINE | ID: mdl-24563355

ABSTRACT

Ran is a small ras-related GTPase that controls the nucleocytoplasmic exchange of macromolecules across the nuclear envelope. It binds to chromatin early during nuclear formation and has important roles during the eukaryotic cell cycle, where it regulates mitotic spindle assembly, nuclear envelope formation and cell cycle checkpoint control. Like other GTPases, Ran relies on the cycling between GTP-bound and GDP-bound conformations to interact with effector proteins and regulate these processes. In nucleocytoplasmic transport, Ran shuttles across the nuclear envelope through nuclear pores. It is concentrated in the nucleus by an active import mechanism where it generates a high concentration of RanGTP by nucleotide exchange. It controls the assembly and disassembly of a range of complexes that are formed between Ran-binding proteins and cellular cargo to maintain rapid nuclear transport. Ran also has been identified as an essential protein in nuclear envelope formation in eukaryotes. This mechanism is dependent on importin-ß, which regulates the assembly of further complexes important in this process, such as Nup107-Nup160. A strong body of evidence is emerging implicating Ran as a key protein in the metastatic progression of cancer. Ran is overexpressed in a range of tumors, such as breast and renal, and these perturbed levels are associated with local invasion, metastasis and reduced patient survival. Furthermore, tumors with oncogenic KRAS or PIK3CA mutations are addicted to Ran expression, which yields exciting future therapeutic opportunities.


Subject(s)
Neoplasm Metastasis , Neoplasms/pathology , Nuclear Envelope/physiology , ran GTP-Binding Protein/metabolism , Active Transport, Cell Nucleus , Cell Cycle , Humans , Protein Conformation , Spindle Apparatus , ran GTP-Binding Protein/chemistry , ran GTP-Binding Protein/physiology
4.
Oncotarget ; 4(10): 1836-43, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24123619

ABSTRACT

USP17 is a cell cycle regulated deubiquitinating enzyme that is highly expressed in tumor-derived cell lines and has an established role in cell proliferation and chemotaxis. This is the first study to examine the clinical significance of USP17 expression in non-small cell lung cancer (NSCLC). USP17 was overexpressed in both squamous and adenocarcinoma NSCLC tissue. Patients with USP17 positive tumors had significantly reduced recurrence-free survival than patients with USP17 negative tumors. Moreover, USP17 was more highly expressed in patients with recurrence of disease at distant sites, suggesting that USP17 levels may correlate with NSCLC distant metastases. Overall, these findings establish USP17 as a potentially valuable novel biomarker for metastatic lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/enzymology , Endopeptidases/metabolism , Lung Neoplasms/enzymology , Adenocarcinoma/enzymology , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Aged , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Growth Processes/physiology , Cell Line, Tumor , Cohort Studies , Disease-Free Survival , Endopeptidases/genetics , Female , Humans , Lung Neoplasms/pathology , Male , Neoplasm Metastasis , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Survival Analysis , Ubiquitination
5.
Breast Cancer Res ; 14(3): R84, 2012 May 23.
Article in English | MEDLINE | ID: mdl-22621373

ABSTRACT

INTRODUCTION: Basal-like breast cancers (BL-BCa) have the worst prognosis of all subgroups of this disease. Hyaluronan (HA) and the HA receptor CD44 have a long-standing association with cell invasion and metastasis of breast cancer. The purpose of this study was to establish the relation of CD44 to BL-BCa and to characterize how HA/CD44 signaling promotes a protease-dependent invasion of breast cancer (BrCa) cells. METHODS: CD44 expression was determined with immunohistochemistry (IHC) analysis of a breast cancer tissue microarray (TMA). In vitro experiments were performed on a panel of invasive BL-BCa cell lines, by using quantitative polymerase chain reaction (PCR), immunoblotting, protease activity assays, and invasion assays to characterize the basis of HA-induced, CD44-mediated invasion. RESULTS: Expression of the hyaluronan (HA) receptor CD44 associated with the basal-like subgroup in a cohort of 141 breast tumor specimens (P = 0.018). Highly invasive cells of the representative BL-BCa cell line, MDA-MB-231 (MDA-MB-231Hi) exhibited increased invasion through a basement membrane matrix (Matrigel) and collagen. In further experiments, HA-induced promotion of CD44 signaling potentiated expression of urokinase plasminogen activator (uPA) and its receptor uPAR, and underpinned an increased cell-associated activity of this serine protease in MDA-MB-231Hi and a further BL-BCa cell line, Hs578T cells. Knockdown of CD44 attenuated both basal and HA-stimulated uPA and uPAR gene expression and uPA activity. Inhibition of uPA activity by using (a) a gene-targeted RNAi or (b) a small-molecule inhibitor of uPA attenuated HA-induced invasion of MDA-MB-231Hi cells through Matrigel. HA/CD44 signaling also was shown to increase invasion of MDA-MB-231 cells through collagen and to potentiate the collagen-degrading activity of MDA-MB-231Hi cells. CD44 signaling was subsequently shown to upregulate expression of two potent collagen-degrading enzymes, the cysteine protease cathepsin K and the matrix metalloprotease MT1-MMP. RNAi- or shRNA-mediated depletion of CD44 in MDA-MB-231Hi cells decreased basal and HA-induced cathepsin K and MT1-MMP expression, reduced the collagen-degrading activity of the cell, and attenuated cell invasion through collagen. Pharmacologic inhibition of cathepsin K or RNAi-mediated depletion of MT1-MMP also attenuated MDA-MB-231Hi cell invasion through collagen. CONCLUSION: HA-induced CD44 signaling increases a diverse spectrum of protease activity to facilitate the invasion associated with BL-BCa cells, providing new insights into the molecular basis of CD44-promoted invasion.


Subject(s)
Breast Neoplasms/metabolism , Collagen/metabolism , Hyaluronan Receptors/metabolism , Hyaluronic Acid/metabolism , Neoplasms, Basal Cell/metabolism , Serine Proteases/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Cathepsin K/metabolism , Cell Line, Tumor , Female , Humans , Hyaluronan Receptors/genetics , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 14/metabolism , Neoplasm Invasiveness , Neoplasm Metastasis , RNA Interference , RNA, Small Interfering , Receptors, Urokinase Plasminogen Activator/metabolism , Signal Transduction , Up-Regulation , Urokinase-Type Plasminogen Activator/genetics , Urokinase-Type Plasminogen Activator/metabolism
6.
Mol Cancer Ther ; 7(3): 548-58, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18347142

ABSTRACT

Effective inhibitors of osteopontin (OPN)-mediated neoplastic transformation and metastasis are still lacking. (-)-Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro. In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas. In this study, we have investigated the effects of (-)-agelastatin A on OPN-mediated malignant transformation using mammary epithelial cell lines. Treatment with (-)-agelastatin A inhibited OPN protein expression and enhanced expression of the cellular OPN inhibitor, Tcf-4. (-)-Agelastatin A treatment also reduced beta-catenin protein expression and reduced anchorage-independent growth, adhesion, and invasion in R37 OPN pBK-CMV and C9 cell lines. Similar effects were observed in MDA-MB-231 and MDA-MB-435s human breast cancer cell lines exposed to (-)-agelastatin A. Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A. Our study reveals, for the very first time, that (-)-agelastatin A down-regulates beta-catenin expression while simultaneously up-regulating Tcf-4 and that these combined effects cause repression of OPN and inhibition of OPN-mediated malignant cell invasion, adhesion, and colony formation in vitro. We have also shown that (-)-agelastatin A inhibits cancer cell proliferation by causing cells to accumulate in the G(2) phase of cell cycle.


Subject(s)
Alkaloids/pharmacology , Cell Adhesion/drug effects , Neoplasm Invasiveness/prevention & control , Osteopontin/physiology , Oxazolidinones/pharmacology , Cell Adhesion/physiology , Cell Division/drug effects , Cell Line, Tumor , Humans , Neoplasm Metastasis/prevention & control , Osteopontin/genetics , Promoter Regions, Genetic , RNA Interference
7.
Cancer Lett ; 237(1): 1-9, 2006 Jun 08.
Article in English | MEDLINE | ID: mdl-15979783

ABSTRACT

The hyaluronan (HA) receptor CD44 has a well documented role in tumour metastasis. This review focuses on the potential significance of CD44 expression and function in regulating the metastasis of both haematological malignancies and solid tumours to the bone. Specifically, the review will discuss the evidence that HA-CD44 interactions facilitate the arrest of circulating malignant cells upon the bone marrow endothelial cells and discuss data that suggests CD44 may orchestrate the ability of tumour cells to regulate the modification of the bone matrix and support its colonisation by malignant cells.


Subject(s)
Bone Neoplasms/secondary , Hematologic Neoplasms/metabolism , Hyaluronan Receptors/metabolism , Neoplastic Cells, Circulating/metabolism , Animals , Bone Marrow/immunology , Bone Marrow/metabolism , Bone Marrow/pathology , Bone Neoplasms/immunology , Bone Neoplasms/metabolism , Bone Remodeling , Cell Adhesion/immunology , Cell Proliferation , Endothelial Cells/immunology , Endothelial Cells/metabolism , Endothelial Cells/pathology , Hematologic Neoplasms/immunology , Hematologic Neoplasms/pathology , Humans , Hyaluronic Acid/metabolism , Neoplastic Cells, Circulating/immunology , Neoplastic Cells, Circulating/pathology
8.
Cancer Res ; 64(16): 5702-11, 2004 Aug 15.
Article in English | MEDLINE | ID: mdl-15313910

ABSTRACT

The aim of this current study was to examine the significance of CD44 expression in mediating cancer cell adhesion to human bone marrow endothelial cell(s) (hBMEC). Differential CD44 expression on two metastatic prostate cancer cell lines, PC3 (CD44 +ve) and DU145 (CD44 -ve) and four breast cancer cell lines was confirmed by immunoblotting and immunocytochemistry. In cell adhesion assays, PC3 but not DU145 cells demonstrated a rapid adhesion to hBMECs. Treatment of PC3 cells with a neutralizing antibody against CD44 standard (CD44s) and CD44 splice variants decreased PC3 cell adhesion to hBMECs. Similarly, depletion of CD44 expression using RNA interference decreased the ability of PC3 cells and two CD44 +ve breast cancer cell lines (MDA-MB-231 and MDA-MB-157) to bind FITC-conjugated hyaluronan (FITC-HA) and to adhere to hBMECs. In contrast, transfection of DU145 cells or the T47D and MCF-7 breast cancer cell lines to express CD44s increased cell surface binding of FITC-HA and cell adherence to hBMECs. Treatment of PC3 and MDA-MD-231 cells but not hBMECs with hyaluronidase attenuated cell adhesion, suggesting that cell surface expression of CD44 on prostate and breast cancer cells may promote the retention of a HA coat that facilitates their initial arrest on bone marrow endothelium.


Subject(s)
Bone Marrow Cells/pathology , Breast Neoplasms/pathology , Hyaluronan Receptors/physiology , Prostatic Neoplasms/pathology , Bone Marrow Cells/metabolism , Breast Neoplasms/metabolism , Cell Adhesion/physiology , Endothelium/metabolism , Endothelium/pathology , Humans , Hyaluronan Receptors/biosynthesis , Hyaluronic Acid/metabolism , Immunohistochemistry , Male , Prostatic Neoplasms/metabolism , RNA Interference
SELECTION OF CITATIONS
SEARCH DETAIL
...